Ganglioside GM2/GD2 Synthetase mRNA Is a Marker for Detection of Infrequent Neuroblastoma Cells in Bone Marrow

This publication has 35 references indexed in Scilit:

• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid
  New England Journal of Medicine, 1999
• Detection of the PGP9.5 and Tyrosine Hydroxylase mRNAs for Minimal Residual Neuroblastoma Cells in Bone Marrow and Peripheral Blood.
  The Tohoku Journal of Experimental Medicine, 1998
• A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma
  Cancer, 1997
• Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction
  Journal of Pediatric Surgery, 1997
• Neuroblastoma cell detection by reverse transcriptase‐polymerase chain reaction (RT‐PCR) for tyrosine hydroxylase mRNA
  International Journal of Cancer, 1994
• Prognostic Value of Immunocytologic Detection of Bone Marrow Metastases in Neuroblastoma
  New England Journal of Medicine, 1991
• Gangliosides of human melanoma
  Cancer, 1989
• Both GA2, GM2, and GD2 synthases and GM1b, GD1a, and GT1b synthases are single enzymes in Golgi vesicles from rat liver.
  Proceedings of the National Academy of Sciences, 1988
• Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2
  Cellular Immunology, 1988
• Association of Multiple Copies of the N-mycOncogene with Rapid Progression of Neuroblastomas
  New England Journal of Medicine, 1985